Author

T. Prazuck

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 7 Organism:human· 4 Assay:proteomics· 4 Organism:virus· 3 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. Planas· 7 shared F. Porrot· 7 shared I. Staropoli· 7 shared L. Hocqueloux· 7 shared O. Schwartz· 7 shared C. Planchais· 6 shared D. Veyer· 6 shared H. Mouquet· 6 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

D. Planas

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

D. Planas, I. Staropoli, V. Michel, F. Lemoine, F. Donati, M. Prot, F. Porrot, F. G. Benhassine, B. Jeyarajah, A. Brisebarre, O. Dehan, L. Avon, W. Bolland, M. Hubert, J. Buchreiser, , O. Schwartz

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

bioRxiv · Nov 20, 2023 · PreprintMicrobiology

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

W. Bolland, V. Michel, D. Planas, M. Hubert, F. Guivel-Benhassine, F. Porrot, I. Staropoli, M. N'Debi, C. Rodriguez, S. Fourati, M. Prot, C. Planchais, L. Hocqueloux, E. Simon-Loriere, H. Mouquet, , J. Buchrieser

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

bioRxiv · Sep 6, 2023Microbiology

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

D. Planas, T. Bruel, I. Staropoli, F. Guivel-Benhassine, F. Porrot, P. Maes, L. Grzelak, M. Prot, S. Mougari, C. Planchais, J. Puech, M. Saliba, R. Sahraoui, F. Femy, N. Morel, , O. Schwartz

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

bioRxiv · Nov 17, 2022Microbiology

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

N. Saunders, D. Planas, W. H. Bolland, C. Rodriguez, S. Fourati, J. Buchrieser, C. Planchais, M. Prot, I. Staropoli, F. Guivel-Benhassine, F. Porrot, D. Veyer, H. Pere, N. Robillard, M. Saliba, , O. Schwartz

This study examines the fusogenicity and neutralization sensitivity of the SARS-CoV-2 AY.4.2 sublineage compared to the Delta variant, finding similar spike function but reduced neutralization sensitivity to certain antibodies and vaccines.

bioRxiv · Jan 7, 2022Microbiology

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

D. Planas, N. Saunders, P. Maes, F. G. Benhassine, C. Planchais, F. Porrot, I. Staropoli, F. Lemoine, H. Pere, D. Veyer, J. Puech, J. Rodary, W. H. Bolland, J. Buchrieser, G. Baele, , O. Schwartz

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

bioRxiv · Dec 14, 2021Immunology

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, , O. Schwartz

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

bioRxiv · May 26, 2021 · PreprintMicrobiology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, S. Behillil, V. Enouf, M. Marianne, , O. Schwartz

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.

bioRxiv · Feb 12, 2021 · PreprintImmunology